Applied Molecular Transport Announces Publication in Tissue Barriers Providing Additional Insight into Company’s Proprietary Technology Platform
13 Abril 2022 - 7:00AM
Applied Molecular Transport Inc. (Nasdaq: AMTI) (AMT), a
clinical-stage biopharmaceutical company, today announced that new
insights into the unique mechanism of action utilized by its oral
biologic product candidates, including lead clinical programs
AMT-101 and AMT-126, have been published in Tissue Barriers. Oral
AMT-101 and AMT-126 are in development to treat diseases associated
with immune dysregulation and intestinal epithelial (IE) barrier
defects, such as ulcerative colitis (UC), pouchitis and rheumatoid
arthritis (RA). The article, entitled “GRP75 as a Functional
Element of Cholix Transcytosis,” was published in the online
edition of Tissue Barriers.
“We are excited to share additional insights
into our breakthrough platform technology, which enables active
transport of oral biologics across the intestinal epithelial
barrier,” said Randall Mrsny, PhD, chief scientific officer and
co-founder of AMT. “Specifically, the interactions between the
cholix carrier and intracellular elements, including GRP75, play a
critical role to efficiently traffic our oral biologics through a
privileged and protected pathway into the intestinal lamina
propria. The elucidation of this unique pathway enables application
of our technology platform to a wide range of intra- and
extracellular disease targets in mucosal immunology and other
therapeutic areas."
The research published in Tissue Barriers
highlights how AMT’s proprietary technology platform selectively
drives the transcytosis pathway, uniquely enabling the active and
efficient transport of biological therapeutics through intestinal
epithelial cells, making AMT’s oral biologic candidates highly
differentiated from injectable biologics.
About AMT-101AMT-101 is a novel
GI-selective, oral fusion of IL-10 and AMT’s proprietary carrier
molecule, currently in development in four Phase 2 clinical trials
in inflammatory bowel diseases and RA. AMT-101 is designed to cross
the IE barrier with limited entry into the bloodstream, thereby
focusing IL-10 at the primary site of inflammation in UC, along the
intestinal tissue lamina propria, potentially avoiding the side
effects observed with systemic administration.
About AMT-126AMT-126 is a novel
GI-selective, oral fusion of hIL-22 and AMT’s proprietary carrier
molecule currently in development for diseases related to IE
barrier defects. IL-22 is a cytokine that repairs structural and
functional defects of the IE barrier and induces microbial defense.
AMT-126 is designed to act locally on the epithelial cells of the
intestinal tissue, thereby repairing the IE barrier and supporting
mucosal healing, potentially translating into clinically meaningful
improvements in a broad range of GI-focused, peripheral
inflammatory, and other diseases.
About Applied Molecular Transport
Inc.AMT is a clinical-stage biopharmaceutical company
leveraging its proprietary technology platform to design and
develop a pipeline of novel oral biologic product candidates to
treat autoimmune, inflammatory, metabolic, and other diseases.
AMT’s proprietary technology platform allows it to exploit existing
natural cellular trafficking pathways to facilitate the active
transport of diverse therapeutic modalities across the IE barrier.
Active transport is an efficient mechanism that uses the cell’s own
machinery to transport materials across the IE barrier. AMT is
developing additional oral biologic product candidates in
patient-friendly oral forms that are designed to either target
local intestinal tissue or enter systemic circulation to precisely
address the relevant pathophysiology of disease.
AMT’s headquarters, internal GMP manufacturing
and lab facilities are located in South San Francisco, CA. For
additional information on AMT, please visit www.appliedmt.com
Forward-Looking StatementsThis
press release contains forward-looking statements as that term is
defined in Section 27A of the Securities Act of 1933 and Section
21E of the Securities Exchange Act of 1934. Such forward-looking
statements involve substantial risks and uncertainties. All
statements other than statements of historical facts contained in
this press release are forward-looking statements including
statements relating to AMT’s plans, expectations, forecasts, and
future events. Such forward-looking statements include, but are not
limited to, the potential of, and expectations regarding AMT’s
technology platform and the extent to which it may enable the
development of new products, statements regarding the optimization
or expansion of our product development plans or the design of
future clinical trials, statements regarding the potential of
AMT-101, AMT-126, AMT’s respiratory carrier technology or regarding
AMT-101 and AMT-126 clinical trials, statements regarding the
potential for AMT’s product candidates to treat or provide
clinically meaningful outcomes for certain medical conditions or
diseases, and assumptions regarding the biological mode of action
of our product candidates and the potential to avoid side effects
with our product candidates. In some cases, you can identify
forward-looking statements by terminology such as “believe,”
“estimate,” “intend,” “may,” “plan,” “potentially,” “will,”
“expect,” “enable,” “likely” or the negative of these terms or
other similar expressions. We have based these forward-looking
statements largely on our current expectations and projections
about future events and trends that we believe may affect our
financial condition, results of operations, business strategy and
financial needs. Actual events, trends or results could differ
materially from the plans, intentions and expectations disclosed in
these forward-looking statements based on various factors.
Information regarding the foregoing and additional risks may be
found in the section entitled “Risk Factors” in AMT’s Annual and
Quarterly Reports on Form 10-K and 10-Q filed with the Securities
and Exchange Commission (the “SEC”), and AMT’s future reports to be
filed with the SEC. These forward-looking statements are made as of
the date of this press release, and AMT assumes no obligation to
update the forward-looking statements, or to update the reasons why
actual results could differ from those projected in the
forward-looking statements, except as required by law.
Investor Relations
Contact:Andrew ChangHead, Investor Relations &
Corporate Communicationsachang@appliedmt.com
Media Contacts:Alexandra
SantosWheelhouse Life Science Advisorsasantos@wheelhouselsa.com
Aljanae ReynoldsWheelhouse Life Science
Advisorsareynolds@wheelhouselsa.com
Applied Molecular Transp... (NASDAQ:AMTI)
Gráfica de Acción Histórica
De Sep 2024 a Oct 2024
Applied Molecular Transp... (NASDAQ:AMTI)
Gráfica de Acción Histórica
De Oct 2023 a Oct 2024